Healthcare Analysts, along with Dr. David Eichenbaum, discuss the current state and future direction in Geographic Atrophy (GA) (relevant companies APLS, ANNX, BLTE, JNJ, MITO, NVS REGN) on an Analyst/Industry conference call to be held on April 7 at 4:30 pm.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $31 from $30 at Scotiabank
- Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
- Apellis announces FDA acceptance, priority review of sNDA for EMPAVELI
- Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
- Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli